Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study

Abstract Background Despite the effectiveness of the various targeted therapies currently approved for solid tumors, acquired resistance remains a persistent problem that limits the ultimate effectiveness of these treatments. Polyclonal resistance to targeted therapy has been described in multiple s...

Повний опис

Бібліографічні деталі

Автори:	Arnaud Bayle, Laila Belcaid, Lola-Jade Palmieri, Diego Teysonneau, Sophie Cousin, Mariella Spalato-Ceruso, Mihaela Aldea, Damien Vasseur, Melissa Alame, Laura Blouin, Isabelle Soubeyran, Claudio Nicotra, Maud Ngocamus, Antoine Hollebecque, Yohann Loriot, Benjamin Besse, Ludovic Lacroix, Etienne Rouleau, Fabrice Barlesi, Fabrice Andre, Antoine Italiano
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2023-11-01
Серія:	Molecular Cancer
Предмети:	ctDNA Targeted therapy Resistance biomarkers Next-generation sequencing
Онлайн доступ:	https://doi.org/10.1186/s12943-023-01878-9
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!